Skip to main content
//empty //empty
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Positive Pivotal Data for Libtayo® (cemiplimab) Monotherapy in Locally Advanced Basal Cell Carcinoma Featured as a Late-breaking Presentation at ESMO
- PR Newswire - Fri Sep 18, 2:05AM CDT
PR Newswire - PRNW
Fri Sep 18, 2:05AM CDT
TARRYTOWN, N.Y. and PARIS , Sept. 18, 2020 /PRNewswire/ -- 
Retinal Disease Therapeutics Market to Rise at 8.6% CAGR and Reach USD 21,318.0 Million by 2026, Facilitated by Increasing Regulatory Approvals for Favouring Drugs, says Fortune Business Insights
- GlobeNewswire - Wed Sep 16, 4:43AM CDT
GlobeNewswire - CMTX
Wed Sep 16, 4:43AM CDT
The global retinal disease therapeutics market is likely to expand at an impressive rate driven by recent government participation towards prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled "Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026," the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.
Look for Shares of Regeneron Pharm to Potentially Pullback after Yesterday's 2.80% Rise
- Comtex SmarTrend(R) - Tue Sep 15, 12:37PM CDT
Comtex SmarTrend(R) - CMTX
Tue Sep 15, 12:37PM CDT
Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $567.89 to a high of $580.52. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $572.80 on volume of 59,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Regeneron and University of Lausanne Publish Newomics M3 Emitters
- BusinessWire - Tue Sep 15, 11:00AM CDT
BusinessWire - CMTX
Tue Sep 15, 11:00AM CDT
Newomics Inc., a commercial-stage biotechnology company that sells and develops mass spectrometry products and services, today announced that its award-winning multinozzle emitters (Newomics(R) M3 emitters) were featured in two publications from Regeneron Pharmaceuticals Inc. and the University of Lausanne, respectively.
Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium
- GlobeNewswire - Mon Sep 14, 8:30AM CDT
GlobeNewswire - CMTX
Mon Sep 14, 8:30AM CDT
High-throughput clinical assay detects, quantifies SARS-CoV-2-neutralizing antibodies
RECOVERY COVID-19 Phase 3 Trial to Evaluate Regeneron's REGN-COV2 Investigational Antibody Cocktail in the UK
- PR Newswire - Mon Sep 14, 6:00AM CDT
PR Newswire - PRNW
Mon Sep 14, 6:00AM CDT
TARRYTOWN, N.Y. and OXFORD, England, Sept. 14, 2020 /PRNewswire/ --
FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
- PR Newswire - Sun Sep 13, 11:59PM CDT
PR Newswire - PRNW
Sun Sep 13, 11:59PM CDT
TARRYTOWN, N.Y. and PARIS , Sept. 14, 2020 /PRNewswire/ --
Dupixent® (dupilumab) Long-term Data Show Sustained Improvement in Lung Function and Reduction in Severe Exacerbations in Adults and Adolescents with Moderate-to-severe Asthma
- PR Newswire - Mon Sep 7, 11:59PM CDT
PR Newswire - PRNW
Mon Sep 7, 11:59PM CDT
TARRYTOWN, N.Y. and PARIS , Sept. 8, 2020 /PRNewswire/ -- 
Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm
- PR Newswire - PRF - Sat Sep 5, 7:30AM CDT
PR Newswire - PRF - CMTX
Sat Sep 5, 7:30AM CDT
, /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of the Company's stockholders.
Kaskela Law LLC Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) and Encourages Long-Term REGN Stockholders to Contact the Firm
- PR Newswire - Sat Sep 5, 7:30AM CDT
PR Newswire - PRNW
Sat Sep 5, 7:30AM CDT
PHILADELPHIA , Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of the Company's stockholders.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies